ATHE vs. VTYX, MDWD, FTLF, CRBU, BTMD, ACTU, BIOA, TVGN, KYTX, and NVCT
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Ventyx Biosciences (VTYX), MediWound (MDWD), FitLife Brands (FTLF), Caribou Biosciences (CRBU), biote (BTMD), Actuate Therapeutics (ACTU), BioAge Labs (BIOA), Tevogen Bio (TVGN), Kyverna Therapeutics (KYTX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.
Alterity Therapeutics vs. Its Competitors
Alterity Therapeutics (NASDAQ:ATHE) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
In the previous week, Alterity Therapeutics had 1 more articles in the media than Ventyx Biosciences. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.73 beat Alterity Therapeutics' score of 0.47 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
Alterity Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 158.62%. Ventyx Biosciences has a consensus target price of $7.50, indicating a potential upside of 226.09%. Given Ventyx Biosciences' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than Alterity Therapeutics.
2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Alterity Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Alterity Therapeutics' return on equity of 0.00% beat Ventyx Biosciences' return on equity.
Summary
Alterity Therapeutics beats Ventyx Biosciences on 5 of the 9 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATHE) was last updated on 9/16/2025 by MarketBeat.com Staff
Free ATHE Stock Alerts